Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATM-AVI in Pediatric Participants with Serious Gram-Negative Bacterial Infections
NCT05639647Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2023
- Primary completion
- Mar 2027
- Modality
- Covalent Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of aztreonam + avibactam in Gram-negative bacterial infection (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Predicted Plasma Concentration of ATM and AVI at 15 days, Minimum Predicted Trough Plasma Concentration of ATM and AVI at 15 days and 8 more. Started Apr 2023; status: recruiting.
02
Drugs
aztreonam + avibactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT05639647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639647.